ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP

Sponsor
Anhui Provincial Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02830984
Collaborator
(none)
160
1
2
12
13.3

Study Details

Study Description

Brief Summary

Endoscopic retrograde cholangiopancreatography (ERCP) has become one of the most important techniques in the treatment of bile duct stones. A number of studies have been conducted using large-balloon dilation (LBD) after adequate EST to extract large bile duct stones. In those studies, the authors suggested that EST plus LBD might lower the risk of post procedure pancreatitis (PEP) by directing balloon dilation toward the bile duct rather than the pancreatic duct. It has been reported that EPBD followed by insertion of nasobiliary drainage catheter can prevent PEP. However, it is still unclear that nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation for preventing postoperative pancreatitis in treating of large bile duct stones.The investigators therefore designed a prospective randomized trial to determine whether nasobiliary drainage prevent PEP after endoscopic sphincterotomy plus LBD for the treatment of large bile duct stones.

Condition or Disease Intervention/Treatment Phase
  • Procedure: EST+LBD+ENBD
  • Procedure: EST+LBD
N/A

Detailed Description

Patients enrolled were confirmed the presence of CBD stones using magnetic resonance cholangiopancreatography. Patients with large bile duct stones were randomly assigned to EST+LBD+ENBD group and EST+LBD group. A descriptive analysis will be performed on primary endpoint, containing frequency of number and percentage of patients. A two proportion equality test will be conducted to explore whether incidence rates are different. Descriptive statistics including number (N), mean, median, standard deviation, minimum and maximum, will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Prevention
Official Title:
Nasobiliary Drainage After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing Postoperative Pancreatitis in Treating of Large Bile Duct Stones
Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Jul 1, 2017
Anticipated Study Completion Date :
Jul 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: EST+LBD+ENBD group

Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones

Procedure: EST+LBD+ENBD
Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones

Active Comparator: EST+LBD group

Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones

Procedure: EST+LBD
Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones

Outcome Measures

Primary Outcome Measures

  1. The prophylaxis effect of ENBD on post-ERCP pancreatitis after endoscopic sphincterotomy plus LBD for the treatment of large bile duct stones. [the incidence of post-ERCP pancreatitis at 24 h after ERCP in two groups]

    If the serum amylase of patients elevation and 3 times higher than the normal values after ERCP 24 hours in high risk patients, who also have clinical symptoms, without other acute abdominal diseases,such as gastrointestinal perforation,acute cholecystitia and acute cholangitis and etc. In this condition, it will be defined PEP(post-ERCP pancreatitis). Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.

Secondary Outcome Measures

  1. Compare EST+LBD+ENBD group EST+LBD with group on the incidence of hyperamylasemia/adverse events. [the incidence of hyperamylasemia/adverse events at 24 h after ERCP in two groups]

    Hyperamylasemia will be defined as the serum amylase 3 times more than the upper normal values, without clinical symptoms. During the study, any unexpected medical issue will be called adverse event. Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with visualized bile duct stones ≥12 mm in maximum transverse diameter. - Males and females, age > 18 years.

  • Normal amylase level before undergoing ERCP.

  • Signed inform consent form and agreed to follow-up on time.

Exclusion Criteria:
  • Bleeding diathesis

  • Prior EST or EPBD or ENBD

  • Billroth II or Roux-en-Y anatomy

  • Distal extrahepatic bile duct stenosis

  • Acute pancreatitis

  • Intrahepatic bile duct stones.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University HeFei Anhui China 230001

Sponsors and Collaborators

  • Anhui Provincial Hospital

Investigators

  • Principal Investigator: Shao Feng, MD, Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Anhui Provincial Hospital
ClinicalTrials.gov Identifier:
NCT02830984
Other Study ID Numbers:
  • ENBD-001
First Posted:
Jul 13, 2016
Last Update Posted:
Mar 7, 2017
Last Verified:
Jul 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 7, 2017